KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Gross Margin (2016 - 2025)

Historic Gross Margin for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to 43.83%.

  • Neogenomics' Gross Margin fell 10900.0% to 43.83% in Q4 2025 from the same period last year, while for Dec 2025 it was 43.21%, marking a year-over-year decrease of 7100.0%. This contributed to the annual value of 43.21% for FY2025, which is 7100.0% down from last year.
  • As of Q4 2025, Neogenomics' Gross Margin stood at 43.83%, which was down 10900.0% from 42.84% recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Gross Margin registered a high of 44.92% during Q4 2024, and its lowest value of 32.63% during Q1 2022.
  • Moreover, its 5-year median value for Gross Margin was 41.45% (2023), whereas its average is 40.73%.
  • Examining YoY changes over the last 5 years, Neogenomics' Gross Margin showed a top increase of 113300bps in 2021 and a maximum decrease of -96000bps in 2021.
  • Quarter analysis of 5 years shows Neogenomics' Gross Margin stood at 35.99% in 2021, then grew by 14bps to 40.97% in 2022, then grew by 6bps to 43.45% in 2023, then increased by 3bps to 44.92% in 2024, then fell by -2bps to 43.83% in 2025.
  • Its Gross Margin stands at 43.83% for Q4 2025, versus 42.84% for Q3 2025 and 42.61% for Q2 2025.